drug

SB-121

Phase 1updated 3mo ago

by Scioto Biosciences Inc

Phase 1

community read0 votes

all catalysts(0)

nothing on the calendar yet

Trials studying SB-121

phase128-Day Daily-dose Crossover Study of the Safety and Tolerability of SB-121 (Lactobacillus Reuteri With Sephadex® and Maltose) in Subjects, Ages 15 to 45 Years, Diagnosed With Autistic Disordercompletedn=15

News(0)

no news has mentioned this drug yet

Data sources

ClinicalTrials.gov

last refreshed 39m ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

drug

save

SB-121

Phase 1updated 3mo ago

by Scioto Biosciences Inc

Phase 1

community read0 votes

all catalysts(0)

nothing on the calendar yet

Trials studying SB-121

phase128-Day Daily-dose Crossover Study of the Safety and Tolerability of SB-121 (Lactobacillus Reuteri With Sephadex® and Maltose) in Subjects, Ages 15 to 45 Years, Diagnosed With Autistic Disordercompletedn=15

News(0)

no news has mentioned this drug yet

Data sources

ClinicalTrials.gov

last refreshed 39m ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

SB-121

all catalysts(0)

Trials studying SB-121

News(0)

Report a data issue

comments(0)

SB-121

all catalysts(0)

Trials studying SB-121

News(0)

Report a data issue

comments(0)